Trial Profile

Clinical study of PM-359 in Hepatolenticular-degeneration (Wilson's disease)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 26 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PM 359 (Primary)
Indications Hepatolenticular degeneration
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

26 May 2025 New trial record
19 May 2025 According to Prime Medicine media release, company expects to file an investigational new drug (IND) and/or clinical trial application (CTA) for its Wilson Disease program in the first half of 2026. Initial clinical data from this program is expected in 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com